Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Core Viewpoint - Alterity Therapeutics is advancing its development program for ATH434, a treatment for Multiple System Atrophy, following positive Phase 2 trial results released in January 2025 [1][4]. Group 1: Corporate Update - David Stamler, M.D., CEO of Alterity, will provide a corporate update during a Fireside Chat hosted by MST Access on June 25, 2025, in Australia and June 24, 2025, in the United States [1]. - The focus of the update will be on the progress made in the ATH434 development program since the positive Phase 2 data announcement [1]. Group 2: Webcast Details - The webcast will take place on June 25, 2025, at 9:00 a.m. AEST for Australian participants and on June 24, 2025, at 4:00 p.m. Pacific Time for U.S. participants [2]. - Registration for the Zoom webcast is required, and details will be sent directly upon registration [2]. Group 3: Company Overview - Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson's disease and related disorders [4]. - The company has reported positive data for its lead asset, ATH434, in a Phase 2 clinical trial for Multiple System Atrophy, a rare and rapidly progressive disorder [4]. - Alterity is also conducting a Phase 2 clinical trial for ATH434 in advanced MSA and has a drug discovery platform aimed at generating patentable compounds for neurological diseases [4].